Alcyomics

Alcyomics provides unique non-animal/non-artificial human-based in vitro assays—most notably the patented Skimune® platform—to assess the safety and efficacy of pharmaceuticals, biologics (including monoclonal antibodies), advanced therapies such as cell/gene therapy products, nanomedicines, medical devices, cosmetics and chemicals. Their technology enables early identification of adverse immune reactions with high correlation to clinical outcomes (>80% correlation reported for GvHD). The company’s services are used by pharmaceutical companies to de-risk product portfolios before clinical trials. They have published extensively in peer-reviewed journals.